PTC Therapeutics (PTCT) said Monday that it signed an exclusive global license and collaboration agreement for its PTC518 Huntington's disease program with a subsidiary of Novartis (NVS), and will receive a $1 billion upfront payment.
The company said it will also be entitled to additional payments of up to $1.9 billion based on development, regulatory and sales milestones, plus a profit share in the US and double-digit tiered royalties on international sales.
As part for the deal, PTC Therapeutics said Novartis will be in charge of PTC518's development, manufacturing and commercialization after the completion of the ongoing placebo-controlled portion of a phase 2 trial on PTC518, which is expected in the first half of 2025.
The transaction is expected to close in Q1 2025, said PTC Therapeutics.
PTC Therapeutics shares were up over 20% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。